Skip to main content
SpringerLink
Log in

Clinical Aspects of Immunogenicity to Biopharmaceuticals

  • Chapter
Immunogenicity of Biopharmaceuticals

Part of the book series: Biotechnology: Pharmaceutical Aspects ((PHARMASP,volume VIII))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Albertsson-Wikland, K. 1987. Clinical trial with authentic recombinant somatotropin in Sweden and Finland. Acta Paediatr. Scand. (Suppl.) 331:28–34.

    CAS  Google Scholar 

  • Altman, J.J., Pehuet, M., Slama, G., and Tchoapoutsky, C. 1983. Three cases of allergic reaction to human insulin (Letter). Lancet 2:524.

    PubMed  CAS  Google Scholar 

  • Andersen, O.O. 1973. Insulin antibody formation II: the influence of species difference and method of administration. Acta Endocrinol. 72:33–45.

    PubMed  CAS  Google Scholar 

  • Antignani, A. and Youle, R.J. 2007. The cytokine, GM-CSF, can deliver BCL-XL as an extracellular fusion protein to protect cells from apoptosis and retain differential induction. J. Biol. Chem. 282(15):11246–11254.

    PubMed  CAS  Google Scholar 

  • Antonelli, G., Simeoni, E., Bagnato, F., Pozzilli, C., Turriziani, O., Tesoro, R., Di Marco, P., Gasperini, C., Fieschi, C., and Dianzani, F. 1999. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J. Neurol. Sci. 168:131–136.

    PubMed  CAS  Google Scholar 

  • Arnon, R. and Aharoni, R. 2004. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc. Natl. Acad. Sci. USA 101:14593–14598.

    PubMed  CAS  Google Scholar 

  • Barranco, P. and Lopez-Serrano, M.C. 1998. General and epidemiological aspects of allergic drug reactions. Clin. Exp. Allergy 28(Suppl. 4):61–62.

    PubMed  CAS  Google Scholar 

  • Bekisz, J., Schmeisser, H., Hernandez, J., Goldman, N.D., and Zoon, K.C. 2004. Human Interferons alpha, beta and omega. Growth Factors 22:243–251.

    PubMed  CAS  Google Scholar 

  • Bellomi, F., Scagnolari, C., Tomassini, V., Gasperini, C., Paolillo, A., Pozzilli, C., and Antonelli, G. 2003. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J. Neurol. Sci. 215:3–8.

    PubMed  CAS  Google Scholar 

  • Bennett, C.L., Luminari, S., Nissenson, A.R., Tallman, M.S., Klinge, S.A., McWilliams, N., McKoy, J.M., Kim, B., Lyons, E.A., Trifilio, S.M., Raisch, D.W., Evens, A.M., Kuzel, D.M., Schumock, G.T., Belknap, S.M., Locatelli, F., Rossert, J., and Casadevall, N. 2004. Pure red cell aplasia and epoetin therapy. N. Engl. J. Med. 351:1403–1408.

    PubMed  CAS  Google Scholar 

  • Bergrem, H., Danielson, B.G., Eckardt, K.U., Kurtz, A., and Stridsberg, M. 1993. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer, C., Koch, K.M., and Sciqalla, P., (eds). Erythropoietin: Molecular Physiology and Clinical Application. Marcel Dekker, New York,pp. 265–275.

    Google Scholar 

  • Berman, E., Heller, G., Kempin, S., Gee, T., Tran, L.-L., and Clarkson, B. 1990. Incidence of response and long-term follow up in a patient with hairy cell leukemia treated with recombinant human interferon alfa-2a. Blood 75:839–845.

    PubMed  CAS  Google Scholar 

  • Berson, S.A., Yalow, R.S., Bauman, A., Rothschild, M.A., and Newerly, K. 1956. Insulin-I-131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J. Clin. Invest. 35:170.

    PubMed  CAS  Google Scholar 

  • Bertolotto, A., Gilli, F., Sala, A., Audano, L., Castello, A., Magliola, U., Melis, F., and Giordana, M.T. 2001. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative competitive- PCR method for MxA quantification. J. Immunol. Methods 256:141–152.

    PubMed  CAS  Google Scholar 

  • Bertolotto, A., Gilli, F., Sala, A., Capobianco, M., Malucchi, S., Milano, E., Melis, F., Marnetto, F., Lindberg, R.L., Bottero, R., Di Sapio, A., and Giordana, M.T. 2003. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60:634–639.

    PubMed  CAS  Google Scholar 

  • Bertolotto, A., Malucchi, S., Milano, E., Castello, A., Capobianco, M., and Mutani, R. 2000. Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 49:95–100.

    Google Scholar 

  • Bijvoet, A.G.A., Van Hirtum, H., Kroos, M.A., Van de Kamp, E.H., Schoneveld, O., Visser, P., Brakenhoff, J.P., Weggeman, M., van Corven, E.J., Van der Ploeg, A.T., and Reuser, A.J. 1999. Human α-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum. Mol. Genet. 8:2145–2153.

    PubMed  CAS  Google Scholar 

  • Blandford, R.L., Sewell, H., Sharp, P., and Hearnshaw, J.R. 1982. Generalized allergic reaction with synthetic human insulin (Comment–Letter). Lancet 2:1468.

    Google Scholar 

  • Bonetti, P., Diodati, G., Drago, C., Casarin, C., Scaccabarozzi, S., Realdi, G., Ruol, A., and Alberti, A. 1994. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J. Hepatol. 20:416–420.

    PubMed  CAS  Google Scholar 

  • Bray, G.L., Gomperts, E.D., Courter, S., Gruppo, R., Gordon, E.M., Manco-Jonshon, M., Shapiro, A., Scheibel, E., White, G., and Lee, M. 1994. A multicentre study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemofilia A. Blood 83:2428–2435.

    PubMed  CAS  Google Scholar 

  • Brenner, T., Arnon, R., Sela, M., Abramsky, O., Meiner, Z., Riven-Kreitman, R., Tarcik, N., and Teitelbaum, D. 2001. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxoneâ„¢. J. Neuroimmunol. 115:152–160.

    PubMed  CAS  Google Scholar 

  • Bristol, A. 1993. Recombinant DNA derived insulin analogues as potentially useful therapeutic agents. Trends Biotechnol. 11:301–305.

    Google Scholar 

  • Carveth-Johnson, A.O., Mylvaganam, K., and Child, D.F. 1982. Generalised allergic reaction with synthetic human insulin (Letter). Lancet 2:1287.

    PubMed  CAS  Google Scholar 

  • Casadevall, N. 2002. Antibodies against rHuEPO: native and recombinant. Nephrol. Dial. Transplant. 17(Suppl. 5):42–47.

    PubMed  CAS  Google Scholar 

  • Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B., and Mayeux, P. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469–475.

    PubMed  CAS  Google Scholar 

  • Chance, R.E., Root, M.A., and Galloway, J.A. 1976. The immunogenicity of insulin preparations. Acta Endocrinol. Suppl. (Copenh) 205:185–198.

    CAS  Google Scholar 

  • Charak, B., Agah, R., and Mazumder, A. 1993. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood 81:3474–3479.

    PubMed  CAS  Google Scholar 

  • Chen, J.W., Frystyk, J., Lauritzen, T., and Christiansen, J.S. 2005. Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes. Eur. J. Endocrinol. 153(6):907–913.

    PubMed  CAS  Google Scholar 

  • Clanet, M., Radue, E.W., Kappos, L., Hartung, H.P., Hohlfeld, R., Sandberg-Wollheim, M., Kooijmans-Coutinho, M.F., Tsao, E.C., Sandrock, A.W., and European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators. 2002. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507–1517.

    PubMed  CAS  Google Scholar 

  • Comi, G., Filippi, M., and Wolinsky, J.S. 2001. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49:290–297.

    PubMed  CAS  Google Scholar 

  • Davidson, J.K. and DeBra, D.W. 1978. Immunologic insulin resistance. Diabetes 27:307–318.

    PubMed  CAS  Google Scholar 

  • Deckert, T. 1985. The immunogenicity of new insulins. Diabetes 34(Suppl. 2):94–96.

    PubMed  CAS  Google Scholar 

  • Deisenhammer, F., Reindl, M., Harvey, J., Gasse, T., Dilitz, E., and Berger, T. 1999. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 62:1239–1243.

    Google Scholar 

  • Deleeuw, I., Delvigne, C., and Beckaert, J. 1982. Insulin allergy treated with human insulin (recombinant DNA). Diabetes Care 5(Suppl. 2):168–170.

    Google Scholar 

  • deShazo, R.D., Levinson, A.I., Boehm, T., Evans, R. III, and Waed, G. Jr. 1977. Severe persistent biphasic local (immediate and late) skin reactions to insulin. J. Allergy Clin. Immunol. 59:161–164.

    PubMed  CAS  Google Scholar 

  • DeWitt, D.E. and Hirsch, I.B. 2003. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: a scientific review. JAMA 289:2254–2264.

    PubMed  CAS  Google Scholar 

  • Dianzani, F., Antonelli, G., Amicucci, P., Cefaro, A., and Pintus, C. 1989. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients. J. Interferon Res. 9(Suppl. 1):S33–S36.

    PubMed  Google Scholar 

  • Douglas, D.D., Rakela, J., Lin, H.J., Hollinger, F.B., Taswell, H.F., Czaja, A.J., Gross, J.B., Anderson, M.L., Parent, K., and Fleming, C.R. 1993. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig. Dis. Sci. 38:601–607.

    PubMed  CAS  Google Scholar 

  • Eckardt, K.U. and Casadevall, N. 2003. Pure red cell aplasia due to anti-erythropoietin antibodies. Nephrol. Dial. Transplant. 18:865–869.

    PubMed  Google Scholar 

  • Ehrenforth, S., Kreuz, W., Scharrer, I., Linde, R., Funk, M., Gungor, T., Krackhardt, B., and Kornhuber, B. 1992. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594–598.

    PubMed  CAS  Google Scholar 

  • Farina, C., Weber, M.S., Meinl, E., Wekerle, H., and Hohlfeld, R. 2005. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 4:567–575.

    PubMed  CAS  Google Scholar 

  • Fernandez, O., Guerrero, M., Mayorga, C., Munoz, L., Lean, A., Lugue, G., Hervas, M., Fernandez, V., Capdevila, A., and de Ramon, E. 2002. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. J. Neurol. 249:1058–1062.

    PubMed  CAS  Google Scholar 

  • Figlin, R.A.and Itri, L. 1988. Anti-interfeon antibodies: a perspective. Semin. Hematol. 25:9–15.

    PubMed  CAS  Google Scholar 

  • Fineberg, S.E. 1994. Insulin allergy and insulin resistance. In: Lebovitz, H.E., (ed). Therapy for Diabetes Mellitus and Related Disorders. American Diabetes Association, Alexandria, Virginia,. pp. 178–184.

    Google Scholar 

  • Fineberg, S.E., Galloway, J.A., Fineberg, N.S., and Goldman J. 1983. Effects of species of origin, purification levels, and formulation on insulin immunogenicity. Diabetes 32:592–599.

    PubMed  CAS  Google Scholar 

  • Fineberg, S.E., Huang, J., Brunelle, R., Gulliya, K.S., and Anderson J.H. 2003. Effect of long-term exposure to insulin Lispro on the induction of antibody response in patients with type 1 or type 2 Diabetes. Diabetes Care 26:89–96.

    PubMed  CAS  Google Scholar 

  • Fireman, P., Fineberg, S.E., and Galloway, J.A. 1982. Development of IgE antibodies to human (recombinant DNA) porcine, and bovine insulins in diabetic subjects. Diabetes Care 5(Suppl. 2):119–125.

    PubMed  Google Scholar 

  • Francis, G.S., Rice, G.P., Alsop, J.C., and PRISMS Study Group. 2005. Interferon beta-1a in MS. Results following development of neutralizing antibodies in PRISMS. Neurol. 65:48–55.

    Google Scholar 

  • Freund, M., von Wussow, P., Diedrich, H., Eisert, R., link, H., Wilke, H., Buchholz, F., LeBlanc, S., Fonatsch, C., Deicher, H., and Poliwoda, H. 1989. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br. J. Haematol. 72:350–356.

    PubMed  CAS  Google Scholar 

  • Frigerio, C., Aubry, M., and Gomez, F. 1997. Desensitization-resistant insulin allergy. Allergy 52:238–239.

    PubMed  CAS  Google Scholar 

  • Frost, H. 2005. Antibody-mediated side effects of recombinant proteins. Toxicology 209:155–160.

    PubMed  CAS  Google Scholar 

  • Garcia-Ortega, P., Knobel, H., and Miranda, A. 1984. Sensitization to human insulin (Letter). BMJ 288:1271.

    PubMed  CAS  Google Scholar 

  • Gneiss, C., Reindl, M., Lutterotti, A., Ehling, R., Egg, R., Khalil, M., Berger, T., and Deisenhammer, F. 2004. Interferon beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult. Scler. 10:507–510.

    PubMed  CAS  Google Scholar 

  • Goodbourn, S., Didcock, L., and Randall, R.E. 2000. Interferons: cells signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81:2341–2364.

    PubMed  CAS  Google Scholar 

  • Gossain, V.V., Rouner, D.R., and Homak, K. 1985. Systemic allergy to human (recombinant DNA) insulin. Ann. Allergy 55:116–118.

    PubMed  CAS  Google Scholar 

  • Grammer, L.C., Roberts, M., Buchanan, T.A., Fitzsimons, R., Metzger, B.E., and Patterson, R. 1987. Specificity of immunoglobulin E and immunoglobulin G against human (recombinant DNA) insulin in human insulin allergy and resistance. J. Lab. Clin. Med. 109:141–146.

    PubMed  CAS  Google Scholar 

  • Gribben, J.G., Devereux, S., Thomas, N.S., Keim, M., Jones, H.M., Goldstone, A.H., and Linch, D.C. 1990. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335:434–437.

    PubMed  CAS  Google Scholar 

  • Hanauer, L. and Batson, J.M. 1961. Anaphylactic shock following insulin injection. Diabetes 10:105–109.

    Google Scholar 

  • Hill, A.D., Redmond, H.P., Austin, O.M., Grace, P.A., and Bouchier-Hayes, D. 1993. Granulocyte-macrophage colony-stimulating factor inhibits tumor growth. Br. J. Surg. 80:1543–1546.

    PubMed  CAS  Google Scholar 

  • Holliday, S.M. and Benfield, P. 1997. Interferon-b-1a. A Review of its pharmacological proprieties and therapeutic potential in multiple sclerosis. BioDrugs 8:317–330.

    PubMed  CAS  Google Scholar 

  • Hooijberg, E., Sein, J.J., van den Berk P.C., Hart, A.A., van der Valk, M.A., Kast, W.M., Melief, C.J., and Hekman, A. 1995. Eradication of large human B-cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin-2. Cancer Res. 55:2627–2634.

    PubMed  CAS  Google Scholar 

  • Ishibashi, O., Kobayashi, M., Maegawa, H., Watanabe, N., Takata, Y., Okuno, Y., and Shigeta, Y. 1986. Can insulin antibodies of diabetic patients distinguish human insulin from porcine insulin? Horm. Metab. Res. 18:470–472.

    PubMed  CAS  Google Scholar 

  • Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M., Richert, R.T., Salazar, A.M., Fisher, J.S., Goodkin, D.E., Granger, C.V., Simon, J.H., Alam, J.J., Bartoszak, D.M., Bourdette, D.N., Braiman, J., Brownscheidle, C.M., Coats, M.E., Cohan, S.L., Dougherty, D.S., Kinkel, R.P., Mass, M.K., Munschauer, F.E., Priore, R.L., Pullicino, P.M., Scherokman, B.J., and Whitham, R.H. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:285–294.

    PubMed  CAS  Google Scholar 

  • Johnson, K.B., Brooks, B.R., Ford, C.C., Goodman, A., Guarnaccia, J., Lisak, R.P., Myers, L.W., Panitch, H.S., Pruitt, A., Rose, J.W., Kachuck, N., and Wolinsky, J.S. 2000. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult. Scler. 6:255–266.

    PubMed  CAS  Google Scholar 

  • Johnson, K.B., Brooks, B.R., Cohen, J.A., Ford, C.C., Goldstein, J., Lisak, R.P., Myers, L.W., Panitch, H.S., Rose, J.W., and Schiffer, R.B. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurol. 45:1268–1276.

    CAS  Google Scholar 

  • Johnson, K.B., Brooks, B.R., Cohen, J.A., Ford, C.C., Goldstein, J., Lisak, R.P., Myers, L.W., Panitch, H.S., Rose, J.W., Schiffer, R.B., Vollmer, T., Weiner, L.P., and Wolinsky, J.S. 1998. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50:701–708.

    PubMed  CAS  Google Scholar 

  • Johnson, K.P., Ford, C.C., Lisak, R.P., and Wolinsky, J.S. 2005. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol. Scand. 111(1):42–47.

    PubMed  CAS  Google Scholar 

  • Jones, G.J. and Itri, L.M. 1986. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer 57:1709–1715.

    PubMed  CAS  Google Scholar 

  • Kaplan, S.L., Underwood, L.E., August, G.P., Bell, J.J., Blethen, S.L., Blizzard, R.M., Brown, D.R., Foley, T.P., Hintz, R.L., and Hopwood, N.J. 1986. Clinical studies with recombinant-DNA-derived methionyl human growth hormone deficient children. Lancet 1:697–700.

    PubMed  CAS  Google Scholar 

  • Kappos, L., Clanet, M., Sandberg-Wollheim, M., Radue, E.W., Hartung, H.P., Hohlfeld, R., Xu, J., Bennett, D., Sandrock, A., Goelz, S., and European Interferon beta-1a IM dose-Comparison Study Investigators. 2005. European interferon beta-1a IM dose-comparison study investigators. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65:40–47.

    PubMed  CAS  Google Scholar 

  • Khan, O.A. and Dhib-Jalbut, S.S. 1998. Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are crossreactive. Neurology 51:1696–1702.

    Google Scholar 

  • Kishnani, P.S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W.L., Lesile, N., Levine, J., Spencer, C., McDonald, M., Li, J., Dumontier, J., Halberthal, M., Chien, Y.H., Hopkin, R., Vijayaraghavan, S., Gruskin, D., Bartholomew, D., van der Ploeg, A., Clancy, J.P., Parini, R., Morin, G., Beck, M., De la Gastine, G.S., Jokic, M., Thurberg, B., Richards, S., Bali, D., Davison, M., Worden, M.A., Chen, Y.T., and Wraith, J.E. 2007. Recombinant human acid (alpha)-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109.

    PubMed  CAS  Google Scholar 

  • Klinge, L., Straub, V., Neudorf, U., Schaper, J., Bosbach, T., Gorlinger, K., Wallot, M., Richards, S., and Voit, T. 2005. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul. Disord. 15:24–31.

    PubMed  CAS  Google Scholar 

  • Kracke, A., von Wussow, P., Al-Masri, A.N., Dalley, G., Windhagen, A., and Heidenreich, F. 2000. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 54:193–199.

    PubMed  CAS  Google Scholar 

  • Kromminga, A. and Schellekens, H. 2005. Antibodies against erythropoietin and other protein-based therapeutics. An overview. Ann. NY Acad. Sci. 1050:257–265.

    PubMed  CAS  Google Scholar 

  • Kumar, D. 1997. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 20:1357–1359.

    PubMed  CAS  Google Scholar 

  • Kuter, D.J. 2000. Future directions with platelet growth factors. Semin. Hematol. 37:41–49.

    PubMed  CAS  Google Scholar 

  • Kuter, D.J. 2007. New thrombopoietic growth factors. Blood 109:4607–4616.

    PubMed  CAS  Google Scholar 

  • Lacroix-Desmazes, S., Bayry, J., Misra, N., Horn, M.P., Villard, S., Pashov, A., Stieltjes, N., d’Oiron, R., Saint-Remy, J.M., Hoebeke, J., Kazatchkine, M.D., Reinbolt, J., Mohanty, D., and Kaveri, S.V. 2002. The prevalence of proteolytic antibodies against factor VIII in Haemophilia A. N. Engl. J. Med. 346:662–667.

    PubMed  CAS  Google Scholar 

  • Lahtela, J.T., Knip, M., Paul, R., Antone, J., and Salmi, J. 1997. Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro: a case report. Diabetes Care 20:71–73.

    PubMed  CAS  Google Scholar 

  • Lang, D.M., Alpern, M.B., Visintainer, P.F., and Smith, S.T. 1991. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann. Intern. Med. 115:270–276.

    PubMed  CAS  Google Scholar 

  • Li, D.K., Zhao, J.G., Paty, D.W., and University of British Columbia MS/MRI Analysis Research Group, and the SPECTRIMS Study Group. 2001. Randomized controlled trial of interferon beta-1a in secondary progressive MS. MRI results. Neurology 56:1505–1513.

    Google Scholar 

  • Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., and Kuter, D. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241–3248.

    PubMed  CAS  Google Scholar 

  • Locatelli, F., Aljama, P., Barany, P., Canaud, B., Carrera, F., Eckardt, K.U., Macdougall, I.C., Macleod, A., Horl, W.H., Wiecek, A., and Cameron, S. 2004. Erythropoiesis-stimulating agents and antibody-mediated pure red cell aplasia: where are we now and where do we go from here? Nephrol. Dial. Transplant. 19:288–293.

    PubMed  CAS  Google Scholar 

  • Lok, A.S., Lai, C.L., and Leung, E.K. 1990. Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and nonmalignant hepatitis B virus-related chronic liver diseases. Hepatology 12:1266–1270.

    PubMed  CAS  Google Scholar 

  • Lundin, K., Berger, L., Blomberg, F., and Wilton, P. 1991. Development of anti-hGH antibodies during therapy with authentic human growth hormone. Acta Paediatr. Scand. 372:167–168.

    CAS  Google Scholar 

  • Lusher, J.M. 2000. Inhibitor antibodies to factor VIII and factor IX: management. Semin. Thromb. Hemost. 26:179–188.

    PubMed  CAS  Google Scholar 

  • Lusher, J.M., Arkin, S., Abildgaard, C.F., and Schwartz, R.S. 1993. Recombinat factor VIII for the treatment of previously untreated patients with haemophilia A. safety, efficacy, and development of inhibitors. N. Engl. J. Med. 328:453–459.

    PubMed  CAS  Google Scholar 

  • Malucchi, S., Capobianco, M., Gilli, F., Marnetto, F., Caldano, M., Sala, A., and Bertolotto, A. 2005. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments. Neurol. Sci. 26:S213–S214.

    PubMed  Google Scholar 

  • Malucchi, S., Sala, A., Gilli, F., Bottero, R., Di Sapio, A., Capobianco, M., and Bertolotto, A. 2004. Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis. Neurol. 62:2031–2037.

    CAS  Google Scholar 

  • Mark, D.F., Lu, S.D., Creasey, A.A., Yamamoto, R., and Lin, L.S. 1984. Site-specific mutagene of the human fibroblast interferon gene. Proc. Natl. Acad. Sci. USA 81:5662–5666.

    PubMed  CAS  Google Scholar 

  • Marshall, M.O., Heding, L.G., Villumsen, J., Akerblom, H.K., Baevre, H., Dahlguist, G., Kiaergaard, J.J., Knip, M., Lindgren, F., and Ludvigsson, J. 1988. Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. Diabetes Res. 9:169–175.

    PubMed  CAS  Google Scholar 

  • Massa, G., Vanderschueren-Lodeweyckx, M., and Bouillon, R. 1993. Five-year follow up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin. Endocrinol. 38:137–142.

    CAS  Google Scholar 

  • Masucci, G., Wersall, P., Raghnammar, P., and Mellstedt, H. 1989. Granulocyte monocyte colony stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. 29:288–292.

    PubMed  CAS  Google Scholar 

  • Mellstedt, H. 1994. Induction of anti-granulocyte-macrophage colony-stimulating factor antibodies against exogenous nonglycosylated GM-CSF: biological implications. J. Inteferon. Res. 14:179–180.

    CAS  Google Scholar 

  • Nguyen, K.B., Salazar-Mather, T.P., Dalod, M.Y., Van Deusen, J.B., Wei, X.O., Liew, F.Y., Caligiuri, M.A., Durbin, J.E., and Biron, C.A. 2002. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 69:4279–4287.

    Google Scholar 

  • Okada, Y., Taira, K., Takano, K., and Hizuka, N. 1987. A case report of growth attenuation during methionyl human growth hormone treatment. Endocrinol. Jpn. 34:621–626.

    PubMed  CAS  Google Scholar 

  • Opdenakker, G., Van den Steen, P.E., Laureys, G., Hunninck, K., and Arnold, B. 2003. Neutralizing antibodies in gene-defective hosts. Trends Immunol. 24:94–100.

    PubMed  CAS  Google Scholar 

  • Peces, R., de la Torre, M., Alcazar, R., and Urra, J.M. 1996. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anaemia. N. Engl. J. Med. 335:523–524.

    PubMed  CAS  Google Scholar 

  • Pestka, S., Krause, C.D., and Walter, M.R. 2004. Interferons, interferon-like cytokines and their receptors. Immunol. Rev. 202:8–32.

    PubMed  CAS  Google Scholar 

  • Peters, A., Klose, O., Hefty, R., Keck, F., and Kerner, W. 1995. The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. Diabet Med. 12:925–930.

    PubMed  CAS  Google Scholar 

  • Petersen, B., Bendtzen, C., Koch-Henriksen, N., Ravnborg, M., Ross, C., Sorensen, P.S., and Danish Multiple Sclerosis Group. 2006. Persistence of neutralizing antibodies after discontinuation of IFNb therapy in patients with remitting-relapsing multiple sclerosis. Mult. Scler. 12:247–252.

    PubMed  Google Scholar 

  • Petersen, B., Bendtzen, K., Koch-Henriksen, N., Ravnborg, M., Ross, C., Sorensen, P.S., and Danish Multiple Sclerosis Study Group. 2006. Persistence of neutralizing antibodies after discontinuation of IFNb therapy in patients with relapsing-remitting multiple sclerosis. Mult. Scler. 12:247–252.

    Google Scholar 

  • Petros, W.P., Rabinowitz, J., Stuart, A.R., Gilbert, C.J., Kanakura, Y., Griffin, J.D., and Peters, W.P. 1992. Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support. Blood 80:1135–1140.

    PubMed  CAS  Google Scholar 

  • Polman, C., Kappos, L., White, R., Dahlke, F., Beckmann, K., Pozzilli, C., Thompson, A., Petkau, J., Miller, D., and European Study Group in Interferon Beta-1b in Secondary Progressive MS. 2003. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurol. 60:37–43.

    CAS  Google Scholar 

  • Polman, C.H., O’Connor, P.W., Havrdova, E., Huthchinson, M., Kappos, L., Miller, D.H., Philips, J.T., Lublin, F.D., Giovannoni, G., Waigt, A., Toal, M., Lynn, F., Panzara, M.A., Sandrock, A.W., and the AFFIRM Investigators. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899–910.

    PubMed  CAS  Google Scholar 

  • Pozzilli, C., Antonimi, G., Bagnato, F., Mainero, C., Tomassini, V., Onesti, E., Fantozzi, R., Galgani, S., Pasqualetti, P., Millefiorini, E., Spadaro, M., Dahlke, F., and Gasperini, C. 2002. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1b: a randomized trial in multiple sclerosis. J. Neurol. 249:50–56.

    PubMed  CAS  Google Scholar 

  • Prabhakar, S.S. and Muhlfelder, T. 1997. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin. Nephrol. 47:331–335.

    PubMed  CAS  Google Scholar 

  • PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group. 1998. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 352:1498–1504.

    Google Scholar 

  • PRISMS-Study Group and the University of British Columbia MS/MRI Analysis Group. 2001. PRISMS-4. Long term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628–1636.

    Google Scholar 

  • Quesada, J.R., Rios, A., Swanson, D., Trown, P., and Gutterman, J.U. 1985. Antitumor activity of recombinant derived interferon alpha in metastatic renal cell carcinoma. J. Clin. Oncol. 3:1522–1528.

    PubMed  CAS  Google Scholar 

  • Ragnhammar, P., Frodin, J.E., Trotta, P.P., and Mellstedt, H. 1994a. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol. Immunother. 39:254–262.

    CAS  Google Scholar 

  • Ragnhammar, P., Friesen, H.J., Frodin, J.E., Lefvert, A.K., Hassan, M., Osterborg, A., and Mellstedt, H. 1994b. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in non-immunocompromised patients. Blood 84:4078–4087.

    CAS  Google Scholar 

  • Rauschka, H., Farina, C., Sator, P., Gudek, S., Breier, F., and Schmidbauer, M. 2005. Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology 64:1481–1482.

    PubMed  CAS  Google Scholar 

  • Reeves, W.G. and Kelly, U. 1982. Insulin antibodies induced by bovine insulin therapy. Clin. Exp. Immunol. 50:163–170.

    PubMed  CAS  Google Scholar 

  • Riedl, M.A. and Casillas, A.M. 2003. Adverse drug reactions: types and treatment options. Am. Fam. Physician 68:1781–1790.

    PubMed  Google Scholar 

  • Rini, B., Wadhwa, M., Bird, C., Small, E., Gaines-Das, R., and Thorpe, R. 2005. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine 29:56–66.

    PubMed  CAS  Google Scholar 

  • Rudick, R.A., Simonian, N.A., Alam, J.A., Campion, M., Scaramucci, J.O., Jones, W., Coats, M.E., Goodkin, D.E., Weinstock-Guttman, B., Herndon, R.M., Mass, M.K., Richert, J.R., Salazar, A.M., Munschauer, F.E., Cookfair, D.L., Simon, J.H., and Jacobs, L.B. 1998. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50:1266–1272.

    PubMed  CAS  Google Scholar 

  • Rudick, R.A., Stuart, W.H., Calabresi, P.A., Confraveux, C., Galetta, S.L., Radue, E.W., Lublin, F.D., Weinstock-Guttman, B., Wynn, D.R., Lynn, F., Panzara, M.A., Sandrock, A.W., and the SENTINEL Investigators, et al. 2006. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354:911–923.

    PubMed  CAS  Google Scholar 

  • Runkel, L. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm. Res. 15:641–649.

    PubMed  CAS  Google Scholar 

  • Salama, H.H., Hong, J., Zang, Y.C., El-Monqui, A., and Zhang, J. 2003. Blocking effects of serum reactive antibodies induced by galtiramer acetate treatment in multiple sclerosis. Brain 126:2638–2647.

    PubMed  Google Scholar 

  • Sasaki, H., Bothner, B., Dell, A., and Fukuda, M. 1987. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J. Biol. Chem. 262:12059–12076.

    PubMed  CAS  Google Scholar 

  • Schellekens, H. and Casadevall, N. 2004. Immunogenicity of recombinant human proteins: causes and consequences. J. Neurol. 251(Suppl. 2):II4–II9.

    PubMed  Google Scholar 

  • Schernthaner, G. 1993. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16:155–165.

    PubMed  Google Scholar 

  • Skibelli, V., Nissen-Lie, G., and Torjesen, P. 2001. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98:3626–3634.

    Google Scholar 

  • Smith, L.F. 1966. Species variation in the amino acid sequence of insulin. Am. J. Med. 40:662–666.

    PubMed  CAS  Google Scholar 

  • Sorensen, P.S., Deisenhammer, F., Dudac, P., Hohlfeld, R., Myhre, K.M., Palace, J., Polman, C., Pozzilli, C., and Ross, C. for the EFNS Task Force on Anti-IFN-b Antibodies in Multiple Sclerosis. 2005. Guidelines on use of anti-IFN antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-b antibodies in multiple sclerosis. Eur. J. Neurol. 12:817–827.

    PubMed  CAS  Google Scholar 

  • Sorensen, P.S., Koch-Henriksen, N., Ross, C., Clemmesen, K.M., Bendtzen, K., and Danish Multiple Sclerosis Study Group. 2005. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65:33–39.

    PubMed  CAS  Google Scholar 

  • Sorensen, P.S., Ross, C., Clemmesen, K.M., Bendtzen, K., Frederiksen, J.L., Jensen, K., Kristensen, O., Petersen, T., Rasmussen, S., Ravnborg, M., Stenager, E., Koch-Henriksen, N., and the Danish Multiple Sclerosis Study Group. 2003. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184–1191.

    PubMed  CAS  Google Scholar 

  • SPECTRIMS, Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon beta-1a in MS Study Group. 2001. Randomized controlled trial of interferon beta-1a in secondary progressive MS: clinical results. Neurology 56:1496–1504.

    Google Scholar 

  • Spiegel, R.J., Jacobs, S.L., and Treuhaft, M.W. 1989. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective. J. Interferon. Res. 9(Suppl. 1):17–24.

    Google Scholar 

  • Steis, R.G., Smith, J.W., Urba, W.J., Clark, J.W., Itri, L.M., Evans, L.M., Schoenberger, C., and Longo, D.L. 1988. Resistance to recombinant interferon alfa-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med. 318:1409–1413.

    PubMed  CAS  Google Scholar 

  • Takano, K., Shizume, K., and Hibi, I. 1989. Turner’s syndrome: treatment of 203 patients with recombinant human growth hormone for one year. A multicentre study. Acta Endocrinol. 120:559–568.

    PubMed  CAS  Google Scholar 

  • Tangri, S., MothèB.R., Eisenbraun, J., Sidney, J., Southwood, S., Briggs, K., Zinckgraf, J., Bilsel, P., Newman, M., Chesnut, R., LiCalsi, C., and Sette, A. 2005. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol 174:3187–3196.

    PubMed  CAS  Google Scholar 

  • Teitelbaum, D., Fridkis-Hareli, M., Arnon, S., and Sela, M. 1996. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64:209–217.

    PubMed  CAS  Google Scholar 

  • The IFNB Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661.

    Google Scholar 

  • The IFNβ MS Study Group and the University of British Columbia MS/MRI Analysis Group. 1996. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b:experiences during the first three years. Neurology 47:889–894.

    Google Scholar 

  • The IFNβ Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter randomized, double-blind, placebo-controlled trial. Neurology 43:655–661.

    Google Scholar 

  • Tomassini, V., Paolillo, A., Russo, P., Giugni, E., Prosperini, L., Gasperini, C., Antonelli, G., Bastianello, S., and Pozzilli, C. 2006. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J. Neurol. 253:287–293.

    PubMed  CAS  Google Scholar 

  • Ure, D.R. and Rodriguez, M. 2002. Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J. 16:1260–1262.

    PubMed  CAS  Google Scholar 

  • Vallittu, A.M., Halminen, M., Peltonieni, J., Ilonen, J., Julkunen, I., Salmi, A., Eralinna, J.P., and Finnish Beta-Interferon Study Group. 2002. Neutralizing antibodies reduce M×A protein induction in interferon-beta-1a-treated MS patients. Neurology 58:1786–1790.

    PubMed  CAS  Google Scholar 

  • Van Haeften, T.W. 1989. Clinical significance of insulin antibodies in insulin-treated patients. Diabetes Care 9:641–648.

    Google Scholar 

  • Van Hove, J.L.K., Yang, H.W., and Wu, J.Y. 1996. High level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblast from patients with Pompe disease. Proc. Natl. Acad. Sci. USA 93:65–70.

    PubMed  Google Scholar 

  • Velcovsky, H.G., Beringhoff, B., and Federlin, K. 1978. [Immediate type allergy to insulin (author’s translation)]. Immunitat und Infektion 6:146–152.

    PubMed  CAS  Google Scholar 

  • Velcovsky, H.G. and Federlin, K.F. 1982. Insulin-specific IgG and IgE antibody response in type 1 diabetic subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care 5:126–128.

    PubMed  Google Scholar 

  • Verhelst, D., Rossert, J., Casadevall, N., Kruger, A., Eckardt, K.U., and Macdougall, I.C. 2004. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 363:1768–1771.

    PubMed  CAS  Google Scholar 

  • von Wussow, P., Freund, M., Block, B., Diedrich, H., Poliwoda, H., and Deicher. H. 1987. Clinical significance of anti-IFN-a antibody titres during interferon therapy. Lancet 2:635–636.

    Google Scholar 

  • Wadhwa, M., Bird, C., Fagerberg, J., Gaines-Das, R., Ragnhammar, P., Mellstedt, H., and Thorpe, R. 1996. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin. Exp. Immunol. 104:351–358.

    PubMed  CAS  Google Scholar 

  • Walford, S., Allison, S.P., and Reeves, W.G. 1982. The effect of insulin antibodies on insulin dose and diabetic control. Diabetologia 22:106–110.

    PubMed  CAS  Google Scholar 

  • Walsh, G. 2004. Second-generation biopharmaceuticals. Eur. J. Pharm. Biopharm. 58:185–196.

    PubMed  CAS  Google Scholar 

  • Walsh, G. 2005. Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol. 553–558.

    Google Scholar 

  • Witters, L.A., Ohman, J.L., Weir, G.C., Raymond, L.W., and Lowell, F.C. 1977. Insulin antibodies in the pathogenesis of insulin allergy and resistance. Am. J. Med. 63:703–709.

    PubMed  CAS  Google Scholar 

  • Wolinsky, J.S., Narayana, P.A., Johnson, K.B., and Multiple Sclerosis Study Group and the MRI Analysis Center. 2001. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult. Scler. 7:33–41.

    PubMed  CAS  Google Scholar 

  • Yamamoto, K., Takamatsu, J., and Saito, H. 2007. Intavenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review. Int. J. Haematol. 85:287–293.

    CAS  Google Scholar 

  • Zinman, L., Ng, E., and Bril, V. 2007. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68:837–841.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Simona Malucchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Bertolotto
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Copenhagen, Copenhagen, Denmark

    Marco van de Weert

  2. University of Copenhagen, Copenhagen, Denmark

    Eva Horn Møller

Rights and permissions

Reprints and permissions

Copyright information

© 2008 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Malucchi, S., Bertolotto, A. (2008). Clinical Aspects of Immunogenicity to Biopharmaceuticals. In: Weert, M.v., Møller, E.H. (eds) Immunogenicity of Biopharmaceuticals. Biotechnology: Pharmaceutical Aspects, vol VIII. Springer, New York, NY. https://doi.org/10.1007/978-0-387-75841-1_2

Download citation

Publish with us

Policies and ethics

Societies and partnerships

Search

Navigation